News articles about Cardiovascular Systems (NASDAQ:CSII) have trended somewhat positive recently, according to Accern Sentiment Analysis. The research firm identifies negative and positive press coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Cardiovascular Systems earned a media sentiment score of 0.12 on Accern’s scale. Accern also assigned media coverage about the medical device company an impact score of 47.0383848014793 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
Shares of Cardiovascular Systems (CSII) traded down $0.67 during mid-day trading on Friday, reaching $21.92. 203,500 shares of the company’s stock traded hands, compared to its average volume of 336,145. The company has a debt-to-equity ratio of 0.17, a current ratio of 4.65 and a quick ratio of 4.13. The firm has a market capitalization of $750.40, a P/E ratio of -219.18 and a beta of 2.32. Cardiovascular Systems has a 1 year low of $20.58 and a 1 year high of $33.11.
Cardiovascular Systems (NASDAQ:CSII) last announced its earnings results on Wednesday, February 7th. The medical device company reported ($0.01) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.04) by $0.03. Cardiovascular Systems had a negative net margin of 1.62% and a negative return on equity of 0.50%. The company had revenue of $52.63 million for the quarter, compared to analysts’ expectations of $53.39 million. During the same period last year, the firm earned $0.03 earnings per share. The business’s revenue for the quarter was up 5.2% on a year-over-year basis. research analysts forecast that Cardiovascular Systems will post -0.07 earnings per share for the current fiscal year.
A number of equities analysts have issued reports on CSII shares. BidaskClub cut Cardiovascular Systems from a “hold” rating to a “sell” rating in a report on Friday, February 2nd. ValuEngine cut Cardiovascular Systems from a “hold” rating to a “sell” rating in a report on Friday, February 2nd. Needham & Company LLC restated a “buy” rating and issued a $36.00 price objective (down previously from $37.00) on shares of Cardiovascular Systems in a report on Thursday, October 26th. Zacks Investment Research downgraded shares of Cardiovascular Systems from a “buy” rating to a “hold” rating in a research note on Monday, February 12th. Finally, Leerink Swann cut their target price on shares of Cardiovascular Systems from $31.00 to $30.00 and set an “outperform” rating for the company in a research note on Thursday, February 8th. Three analysts have rated the stock with a sell rating, five have issued a hold rating and one has issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $27.00.
ILLEGAL ACTIVITY NOTICE: “Cardiovascular Systems (NASDAQ:CSII) Getting Somewhat Favorable Press Coverage, Report Shows” was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece of content on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/02/23/somewhat-favorable-media-coverage-somewhat-unlikely-to-affect-cardiovascular-systems-csii-share-price.html.
Cardiovascular Systems Company Profile
Cardiovascular Systems, Inc is a medical technology company. The Company is engaged in treating patients suffering from peripheral and coronary artery diseases, including those with arterial calcium. The Company develops an orbital atherectomy technology for both peripheral and coronary commercial applications.
Receive News & Ratings for Cardiovascular Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiovascular Systems and related companies with MarketBeat.com's FREE daily email newsletter.